Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
Krop I, Paulson J, Campbell C, Kiermaier A, Andre F, Fumagalli D, de Haas S, Salgado R, Denkert C, Loibl S, Bailey A, Lewis Phillips G, Frank E, Piccart M, Viale G, Loi S. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. Journal Of Clinical Oncology 2019, 37: 1012-1012. DOI: 10.1200/jco.2019.37.15_suppl.1012.Peer-Reviewed Original ResearchTumor-Infiltrating LymphocytesBreast cancerBetter prognosisComprehensive biomarker analysisPhase III studyInteraction p valueCase-control designBiomarker analysisHigher mRNA expressionAnthracycline useAPHINITY trialAdjuvant trastuzumabChemotherapy typeIII studyImmune signaturesNodal statusImmune markersInfiltrating lymphocytesClinical parametersPoor prognosisPredictive biomarkersTIL analysisBetter outcomesPAM50 subtypesPrognosisThe immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals Of Oncology 2019, 30: 575-581. PMID: 30753274, PMCID: PMC8033534, DOI: 10.1093/annonc/mdz047.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorBreastBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomyMiddle AgedPaclitaxelReceptor, ErbB-2TrastuzumabTumor BurdenTumor MicroenvironmentConceptsHER2-positive breast cancerSmall HER2-positive breast cancersImmune gene signaturesBreast cancerImmune profileAPT trialPD-L1Immune markersImmune microenvironmentSmall HER2-positive tumorsStromal PD-L1 expressionNode-negative breast cancerCell signatureGene signatureHuman epidermal growth factor receptorStromal PD-L1PD-L1 expressionHistological grade 2Luminal B tumorsB cell signaturesBreast cancer trialsHER2-positive tumorsImmune cell signaturesBasal-like tumorsHistological grade 1